Development and Validation of a Combined Ferroptosis and Immune Prognostic Classifier for Hepatocellular Carcinoma

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2021 Jan 11

PMID 33425905

Citations 80

Authors

Yang Liu

Xi Zhang

Junjun Zhang

Juan Tan

Jie Li

Zewen Song

Affiliations

Soon will be listed here.

Abstract

Background: Immunotherapy and sorafenib exert anti-tumor effects via ferroptosis, but reliable biomarkers for the individual treatment and prognosis prediction of hepatocellular carcinoma (HCC) based on the ferroptosis and immune status remain lacking.

Methods: Ferroptosis-related genes (FRGs) were identified by downloading data from FerrDb and by searching and reading original articles from PubMed. Immune-related genes (IRGs) were downloaded from ImmPort. Prognostic FRGs and IRGs in the GSE14520 ( = 220) and The Cancer Genome Atlas (TCGA, = 365) datasets were identified. Least absolute shrinkage and selection operator (LASSO) Cox regression and multivariate Cox regression were used for model construction. Ferroptosis expression profiles, the infiltration of immune cells, and the somatic mutation status were analyzed and compared.

Results: Twenty-seven prognostic ferroptosis- and immune-related signatures were included to construct a comprehensive index of ferroptosis and immune status (CIFI). A subgroup of patients was identified as having a high CIFI value, which was associated with a worse prognosis. This subgroup of patients had significantly up-regulated expressions of many suppressors of ferroptosis and higher fractions of immunosuppressive cells, such as cancer-associated fibroblasts (CAFs) and myeloid-derived suppressor cells (MDSCs). Notably, somatic mutation analysis indicated that high-CIFI patients had higher levels of tumor heterogeneity and higher mutation frequencies of genes like TP53.

Conclusion: In this work, a novel prognostic classifier was developed based on ferroptosis- and IRGs in HCC, and this classifier could be used for prognostic prediction and the selection of patients for immunotherapies and targeted therapies.

Citing Articles

Ferroptosis: insight into the treatment of hepatocellular carcinoma.

Liao C, He Y, Luo X, Deng G Cancer Cell Int. 2024; 24(1):376.

PMID: 39538215 PMC: 11562710. DOI: 10.1186/s12935-024-03559-z.

Comprehensive Analysis of Angiogenesis and Ferroptosis Genes for Predicting the Survival Outcome and Immunotherapy Response of Hepatocellular Carcinoma.

Wang P, Kong G J Hepatocell Carcinoma. 2024; 11:1845-1859.

PMID: 39364435 PMC: 11448465. DOI: 10.2147/JHC.S483647.

Recent progress of ferroptosis in cancers and drug discovery.

Wang X, Ren X, Lin X, Li Q, Zhang Y, Deng J Asian J Pharm Sci. 2024; 19(4):100939.

PMID: 39246507 PMC: 11378902. DOI: 10.1016/j.ajps.2024.100939.

Exploration of lncRNA/circRNA-miRNA-mRNA network in patients with chronic atrophic gastritis in Tibetan plateau areas based on DNBSEQ-G99 RNA sequencing.

Pan W, Liu C, Ren T, Chen X, Liang C, Wang J Sci Rep. 2024; 14(1):9212.

PMID: 38649401 PMC: 11035649. DOI: 10.1038/s41598-024-59836-4.

Zong K, Lin C, Luo K, Deng Y, Wang H, Hu J BMC Cancer. 2024; 24(1):496.

PMID: 38637761 PMC: 11027313. DOI: 10.1186/s12885-024-12265-y.

References

Zheng S, Zou Y, Liang J, Xiao W, Yang A, Meng T . Identification and validation of a combined hypoxia and immune index for triple-negative breast cancer. Mol Oncol. 2020; 14(11):2814-2833. PMC: 7607163. DOI: 10.1002/1878-0261.12747. View

Lin Y, Yang X, Liu W, Li B, Yin W, Shi Y . Chemerin has a protective role in hepatocellular carcinoma by inhibiting the expression of IL-6 and GM-CSF and MDSC accumulation. Oncogene. 2017; 36(25):3599-3608. DOI: 10.1038/onc.2016.516. View

Feng J, Lu P, Zhu G, Hooi S, Wu Y, Huang X . ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma. Acta Pharmacol Sin. 2020; 42(1):160-170. PMC: 7921679. DOI: 10.1038/s41401-020-0439-x. View

Carlson B, Tobe R, Yefremova E, Tsuji P, Hoffmann V, Schweizer U . Glutathione peroxidase 4 and vitamin E cooperatively prevent hepatocellular degeneration. Redox Biol. 2016; 9:22-31. PMC: 4900515. DOI: 10.1016/j.redox.2016.05.003. View

Chen D, Fan Z, Rauh M, Buchfelder M, Eyupoglu I, Savaskan N . ATF4 promotes angiogenesis and neuronal cell death and confers ferroptosis in a xCT-dependent manner. Oncogene. 2017; 36(40):5593-5608. PMC: 5633655. DOI: 10.1038/onc.2017.146. View

Racle J, de Jonge K, Baumgaertner P, Speiser D, Gfeller D . Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife. 2017; 6. PMC: 5718706. DOI: 10.7554/eLife.26476. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S . Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2014; 261(5):947-55. DOI: 10.1097/SLA.0000000000000710. View

Textor S, Fiegler N, Arnold A, Porgador A, Hofmann T, Cerwenka A . Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res. 2011; 71(18):5998-6009. DOI: 10.1158/0008-5472.CAN-10-3211. View

10.

Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R . Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2015; 63(1):173-84. PMC: 4688087. DOI: 10.1002/hep.28251. View

11.

Friedman J, Hastie T, Tibshirani R . Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33(1):1-22. PMC: 2929880. View

12.

Chiu D, Tse A, Xu I, Cui J, Lai R, Li L . Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma. Nat Commun. 2017; 8(1):517. PMC: 5593860. DOI: 10.1038/s41467-017-00530-7. View

13.

Zhang Z, Guo M, Li Y, Shen M, Kong D, Shao J . RNA-binding protein ZFP36/TTP protects against ferroptosis by regulating autophagy signaling pathway in hepatic stellate cells. Autophagy. 2019; 16(8):1482-1505. PMC: 7469536. DOI: 10.1080/15548627.2019.1687985. View

14.

Doll S, Proneth B, Tyurina Y, Panzilius E, Kobayashi S, Ingold I . ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2016; 13(1):91-98. PMC: 5610546. DOI: 10.1038/nchembio.2239. View

15.

Ou Y, Wang S, Li D, Chu B, Gu W . Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses. Proc Natl Acad Sci U S A. 2016; 113(44):E6806-E6812. PMC: 5098629. DOI: 10.1073/pnas.1607152113. View

16.

Louandre C, Ezzoukhry Z, Godin C, Barbare J, Maziere J, Chauffert B . Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer. 2013; 133(7):1732-42. DOI: 10.1002/ijc.28159. View

17.

Jennis M, Kung C, Basu S, Budina-Kolomets A, Leu J, Khaku S . An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev. 2016; 30(8):918-30. PMC: 4840298. DOI: 10.1101/gad.275891.115. View

18.

Mroz E, Tward A, Tward A, Hammon R, Ren Y, Rocco J . Intra-tumor genetic heterogeneity and mortality in head and neck cancer: analysis of data from the Cancer Genome Atlas. PLoS Med. 2015; 12(2):e1001786. PMC: 4323109. DOI: 10.1371/journal.pmed.1001786. View

19.

Jin Z, Lei L, Lin D, Liu Y, Song Y, Gong H . IL-33 Released in the Liver Inhibits Tumor Growth via Promotion of CD4 and CD8 T Cell Responses in Hepatocellular Carcinoma. J Immunol. 2018; 201(12):3770-3779. DOI: 10.4049/jimmunol.1800627. View

20.

Bryceson Y, March M, Ljunggren H, Long E . Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2005; 107(1):159-66. PMC: 1895346. DOI: 10.1182/blood-2005-04-1351. View